Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo

NeuroToxicology

Volumn 40, Issue , 2014, Pages 23-32

  Kim, Hyo Geun ^a   Moon, Minho ^b,d   Choi, Jin Gyu ^a   Park, Gunhyuk ^a   Kim, Ae Jung ^c   Hur, Jinyoung ^b,e   Lee, Kyung Tae ^a   Oh, Myung Sook ^a  

^a Kyung Hee University   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c Kyunggi University   (South Korea)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Korea Food Research Institute   (South Korea)

Author keywords

Alzheimer's disaese; Amyloid beta oligomer; Donepezil; Inflammation; Microglia

Indexed keywords

AMYLOID BETA OLIGOMER; AMYLOID BETA PROTEIN; BETA ACTIN; CYCLOOXYGENASE 2; DONEPEZIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTOSIS; CELL ACTIVATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; GLIOSIS; HIPPOCAMPUS; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMORY DISORDER; MICROGLIA; MOUSE; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALIA; MUS;

ALZHEIMER'S DISAESE; AMYLOID-BETA OLIGOMER; DONEPEZIL; INFLAMMATION; MICROGLIA;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; HIPPOCAMPUS; INDANS; INFLAMMATION MEDIATORS; MALE; MEMORY DISORDERS; MICE; MICE, INBRED ICR; MICROGLIA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PIPERIDINES; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION FACTOR RELA;

EID: 84888193014     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2013.10.004     Document Type: Article

References (59)

1. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69.
2. Bruce-Keller A.J. Microglial-neuronal interactions in synaptic damage and recovery. J Neurosci Res 1999, 58:191-201.
3. Chen G., Chen K.S., Knox J., Inglis J., Bernard A., Martin S.J., et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000, 408:975-979.
4. Cho S.H., Sun B., Zhou Y., Kauppinen T.M., Halabisky B., Wes P., et al. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J Biol Chem 2011, 286:32713-32722.
5. 1-42 oligomer injection. Neurobiol Learn Mem 2011, 96:306-314.
6. Chromy B.A., Nowak R.J., Lambert M.P., Viola K.L., Chang L., Velasco P.T., et al. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 2003, 42:12749-12760.
7. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005, 8:79-84.
8. De Simone R., Ajmone-Cat M.A., Carnevale D., Minghetti L. Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuroinflammation 2005, 2:4.
9. Dewapriya P., Li Y.X., Himaya S.W., Pangestuti R., Kim S.K. Neoechinulin A suppresses amyloid-beta oligomer-induced microglia activation and thereby protects PC-12 cells from inflammation-mediated toxicity. Neurotoxicology 2013, 35:30-40.
10. Dinamarca M.C., Cerpa W., Garrido J., Hancke J.L., Inestrosa N.C. Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits. Mol Psychiatr 2006, 11:1032-1048.
11. Donev R., Kolev M., Millet B., Thome J. Neuronal death in Alzheimer's disease and therapeutic opportunities. J Cell Mol Med 2009, 13:4329-4348.
12. Dong H., Yuede C.M., Coughlan C.A., Murphy K.M., Csernansky J.G. Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease. Brain Res 2009, 1303:169-178.
13. Eikelenboom P., Veerhuis R., Scheper W., Rozemuller A.J., van Gool W.A., Hoozemans J.J. The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm 2006, 113:1685-1695.
14. Giacobini E. Cholinesterase inhibitors stabilize Alzheimer's disease. Ann N Y Acad Sci 2000, 920:321-327.
15. Hansen R.A., Gartlehner G., Webb A.P., Morgan L.C., Moore C.G., Jonas D.E. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 2008, 3:211-225.
16. Hashimoto M., Kazui H., Matsumoto K., Nakano Y., Yasuda M., Mori E. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease. Am J Psychiatr 2005, 162:676-682.
17. Heneka M.T., O'Banion M.K. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007, 184:69-91.
18. Heneka M.T., O'Banion M.K., Terwel D., Kummer M.P. Neuroinflammatory processes in Alzheimer's disease. J Neural Transm 2010, 117:919-947.
19. Holmes C., Cunningham C., Zotova E., Woolford J., Dean C., Kerr S., et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009, 73:768-774.
20. Hwang J., Hwang H., Lee H.W., Suk K. Microglia signaling as a target of donepezil. Neuropharmacology 2010, 58:1122-1129.
21. Hyman B.T., Van Hoesen G.W., Damasio A.R., Barnes C.L. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984, 225:1168-1170.
22. Imbimbo B.P. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease. Expert Opin Investig Drugs 2009, 18:1147-1168.
23. Jacobson S.A., Sabbagh M.N. Donepezil: potential neuroprotective and disease-modifying effects. Expert Opin Drug Metab Toxicol 2008, 4:1363-1369.
24. Jiang Y., Zou Y., Chen S., Zhu C., Wu A., Liu Y., et al. The anti-inflammatory effect of donepezil on experimental autoimmune encephalomyelitis in C57 BL/6 mice. Neuropharmacology 2013, 73:415-424.
25. Kim S.H., Smith C.J., Van Eldik L.J. Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production. Neurobiol Aging 2004, 25:431-439.
26. Koistinaho M., Koistinaho J. Role of p38 and p44/42 mitogen-activated protein kinases in microglia. Glia 2002, 40:175-183.
27. Krishnan K.R., Charles H.C., Doraiswamy P.M., Mintzer J., Weisler R., Yu X., et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatr 2003, 160:2003-2011.
28. Lacor P.N., Buniel M.C., Furlow P.W., Clemente A.S., Velasco P.T., Wood M., et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007, 27:796-807.
29. Lawrence T., Fong C. The resolution of inflammation: anti-inflammatory roles for NF-kappaB. Int J Biochem Cell Biol 2010, 42:519-523.
30. McGeer P.L., Itagaki S., Tago H., McGeer E.G. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987, 79:195-200.
31. Meunier J., Ieni J., Maurice T. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 2006, 149:998-1012.
32. Moon M., Choi J.G., Nam D.W., Hong H.S., Choi Y.J., Oh M.S., et al. Ghrelin ameliorates cognitive dysfunction and neurodegeneration in intrahippocampal amyloid-beta 1-42 oligomer-injected mice. J Alzheimers Dis 2011, 23:147-159.
33. Moon M., Hong H.S., Nam D.W., Baik S.H., Song H., Kook S.Y., et al. Intracellular amyloid-beta accumulation in calcium-binding protein-deficient neurons leads to amyloid-beta plaque formation in animal model of Alzheimer's disease. J Alzheimers Dis 2012, 29:615-628.
34. Moon M., Song H., Hong H.J., Nam D.W., Cha M.Y., Oh M.S., et al. Vitamin D-binding protein interacts with Abeta and suppresses Abeta-mediated pathology. Cell Death Differ 2013, 20:630-638.
35. Narimatsu N., Harada N., Kurihara H., Nakagata N., Sobue K., Okajima K. Donepezil improves cognitive function in mice by increasing the production of insulin-like growth factor-I in the hippocampus. J Pharmacol Exp Ther 2009, 330:2-12.
36. Pan X.D., Chen X.C., Zhu Y.G., Chen L.M., Zhang J., Huang T.W., et al. Tripchlorolide protects neuronal cells from microglia-mediated beta-amyloid neurotoxicity through inhibiting NF-kappaB and JNK signaling. Glia 2009, 57:1227-1238.
37. Parvathy S., Rajadas J., Ryan H., Vaziri S., Anderson L., Murphy G.M. Abeta peptide conformation determines uptake and interleukin-1alpha expression by primary microglial cells. Neurobiol Aging 2009, 30:1792-1804.
38. Paxinos G., Franklin K.B.J. The mouse brain in stereotaxic coordinates 2001, Academic Press, San Diego. 2nd ed.
39. Pickering M., Cumiskey D., O'Connor J.J. Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol 2005, 90:663-670.
40. Reale M., Iarlori C., Gambi F., Lucci I., Salvatore M., Gambi D. Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients. Exp Gerontol 2005, 40:165-171.
41. Rogers S.L., Doody R.S., Pratt R.D., Ieni J.R. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000, 10:195-203.
42. Rojo L.E., Fernandez J.A., Maccioni A.A., Jimenez J.M., Maccioni R.B. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 2008, 39:1-16.
43. Sakono M., Zako T. Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J 2010, 277:1348-1358.
44. Samuel W., Masliah E., Hill L.R., Butters N., Terry R. Hippocampal connectivity and Alzheimer's dementia: effects of synapse loss and tangle frequency in a two-component model. Neurology 1994, 44:2081-2088.
45. Sarter M., Bodewitz G., Stephens D.N. Attenuation of scopolamine-induced impairment of spontaneous alteration behaviour by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology (Berl) 1988, 94:491-495.
46. Selkoe D.J. Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol 1994, 53:438-447.
47. Shi S., Wang Z., Qiao Z. The multifunctional anti-inflammatory drugs used in the therapy of Alzheimer's disease. Curr Med Chem 2013, 20:2583-2588.
48. Sondag C.M., Dhawan G., Combs C.K. Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia. J Neuroinflammation 2009, 6:1.
49. Streit W.J. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 2002, 40:133-139.
50. Terry A.V., Callahan P.M., Hall B., Webster S.J. Alzheimer's disease and age-related memory decline (preclinical). Pharmacol Biochem Behav 2011, 99:190-210.
51. Tsunekawa H., Noda Y., Mouri A., Yoneda F., Nabeshima T. Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35). Behav Brain Res 2008, 190:224-232.
52. Tyagi E., Agrawal R., Nath C., Shukla R. Cholinergic protection via alpha7 nicotinic acetylcholine receptors and PI3K-Akt pathway in LPS-induced neuroinflammation. Neurochem Int 2010, 56:135-142.
53. Tyagi E., Agrawal R., Nath C., Shukla R. Effect of anti-dementia drugs on LPS induced neuroinflammation in mice. Life Sci 2007, 80:1977-1983.
54. Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003, 421:384-388.
55. Watson D., Castano E., Kokjohn T.A., Kuo Y.M., Lyubchenko Y., Pinsky D., et al. Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease. Neurol Res 2005, 27:869-881.
56. Weninger S.C., Yankner B.A. Inflammation and Alzheimer disease: the good, the bad, and the ugly. Nat Med 2001, 7:527-528.
57. White J.A., Manelli A.M., Holmberg K.H., Van Eldik L.J., Ladu M.J. Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol Dis 2005, 18:459-465.
58. Winblad B., Wimo A., Engedal K., Soininen H., Verhey F., Waldemar G., et al. 3-Year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006, 21:353-363.
59. Yoshiyama Y., Kojima A., Ishikawa C., Arai K. Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. J Alzheimers Dis 2010, 22:295-306.